PSORIATIC ARTHRITIS TREATMENT MARKET ANALYSIS

Key Developments

• In March 2024, Acelyrin, Inc. announced promising results from its global phase 2b/3 clinical trial of izokibep, a small protein therapeutic targeting IL-17A, showing potential as a breakthrough treatment for psoriatic arthritis. Izokibep demonstrated exceptional potency, strong tissue penetration, and a prolonged half-life. The robust product pipeline and the expansion of treatment applications are expected to drive market growth.
• In October 2023,Novartis announced that the FDA had approved an intravenous (IV) formulation of Cosentyx (secukinumab) for treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). This IV option, targeting interleukin-17A (IL-17A), is the only non-TNF-α IV treatment for these conditions.
• In August 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA had approved STELARA (ustekinumab) for treating pediatric patients aged six and older with active psoriatic arthritis (PsA). This expands STELARA's treatment profile, which now includes two indications for pediatric patients, building on its initial 2009 approval for adults with moderate to severe plaque psoriasis (PsO).